Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes is marked by gradual beta-cell failure.
• Exogenous insulin therapy is indicated for various clinical scenarios in type 2 diabetes management.
• Insulin therapy aims to supplement or replace endogenous insulin to achieve glycemic control.

Purpose of the Study:

• To outline the indications and strategies for initiating and adjusting exogenous insulin therapy in type 2 diabetes.
• To describe different insulin regimens, including basal, bolus, and basal-bolus therapies.
• To compare the efficacy and safety of different insulin types.

Main Methods:

• Review of current literature and clinical guidelines on insulin therapy for type 2 diabetes.
• Description of basal insulin (e.g., NPH, glargine) and bolus insulin (e.g., regular, aspart, lispro) administration.
• Discussion of insulin dosing strategies, including augmentation and replacement therapy, and dose adjustments.

Main Results:

• Basal insulin is suitable when some beta-cell function remains; basal-bolus insulin is necessary for beta-cell exhaustion.
• Insulin doses are adjusted based on fasting, preprandial, and postprandial glucose levels.
• Basal glargine insulin shows comparable or better A1C control with less hypoglycemia than NPH insulin.
• Rapid-acting insulins (aspart, lispro) offer similar A1C and quality of life benefits as regular insulin but with improved postprandial glucose control.

Conclusions:

• Exogenous insulin therapy, particularly basal-bolus regimens, is essential for managing advanced type 2 diabetes.
• Personalized insulin dosing and regimen selection are critical for optimizing glycemic control and minimizing hypoglycemia.
• Newer insulin analogs offer advantages in postprandial glucose management and safety profiles.